Europe and America now agree on why cholesterol matters. They still differ on how to act on it.
Table of Contents
1.0 Summary
The 2025 ESC/EAS focused update and the 2026 ACC/AHA guideline were written on opposite sides of the Atlantic, and a comparison published in the European Journal of Preventive Cardiology finds they start from the same biology. LDL cholesterol and the other apolipoprotein B-carrying particles cause atherosclerosis, so the aim is to lower them earlier, further, and for longer. Where the two documents separate is in how that gets organized in a clinic. The European approach sorts a patient into a risk category with a numeric LDL goal attached and escalates treatment until the goal is met. The American approach puts more weight on lifetime risk, a coronary calcium score, apoB and lipoprotein(a), what the treatment will cost the patient in effort, and a conversation about the trade-offs. This is a comparison written by cardiologists rather than a new guideline, and it does not reproduce either document’s actual numbers.
2.0 Key Points
- Both guidelines treat apoB-containing lipoproteins, LDL among them, as a cause of atherosclerotic cardiovascular disease rather than a marker of it.
- Both call for earlier and deeper lowering, wider use of combination therapy, and faster intensification after an acute coronary syndrome and in very high risk patients.
- The European framework links risk category to a predefined LDL goal and a stepwise escalation to reach it.
- The American framework gives more operational weight to lifetime risk, coronary artery calcium, non-HDL cholesterol, apoB, lipoprotein(a), treatment burden, and shared decision-making.
- The practical differences show up in borderline-risk primary prevention, in people with silent plaque, and in anyone who needs more than a statin. The paper reports no new thresholds and no new trial data.
3.0 What both sides settled
For years the argument about cholesterol was partly an argument about whether LDL causes heart disease or merely travels with it. Both of these guidelines write from the settled position: LDL and the other apoB-carrying lipoproteins are causal, and the benefit of treatment tracks how much you lower them, how early you start, and how long you keep it up [1].
From that premise both documents draw the same conclusions. They tolerate less cumulative lifetime exposure to atherogenic particles, they reach for combination therapy sooner rather than maximizing one drug and stopping, they intensify quickly after a heart attack and in very high risk patients, and they use biomarkers and imaging selectively, when the result will change the plan [1].
For a patient that agreement has a practical meaning. What matters is not only how high the cholesterol is today but how many years it has been high, and those years began accumulating well before the first abnormal lab result.
4.0 Where the approaches part
The European document is goal-driven. Risk category determines an LDL target, and the target determines how far treatment escalates. It is legible: a patient can be told the number they are aiming for and whether they have reached it.
The American document is more of a decision framework. It brings lifetime risk, coronary artery calcium, non-HDL cholesterol, apoB, lipoprotein(a), and the burden the treatment places on the patient into the choice of therapy, and it expects a discussion rather than a lookup [1]. That flexibility is useful for the patient whose calculated ten-year risk understates the plaque already in their arteries, and it is harder to audit.
The two styles produce the most divergence in three situations: primary prevention for someone sitting at the borderline of a risk category, people with silent atherosclerosis found on imaging, and anyone who will need drugs beyond a statin [1]. This site’s approach uses calcium scoring and apoB in exactly that borderline territory. See /clinical/04-risk-stratification.html for the risk assessment and /clinical/06-advanced-tools.html for where the advanced biomarkers come in.
5.0 What to take from it
A clinician who was already lowering apoB early and reaching for a second agent rather than waiting is doing what both guidelines ask. The comparison confirms that direction rather than redirecting it [1].
The honest limit of this paper is that it stays at the conceptual level. It does not print the ESC/EAS goal thresholds, the ACC/AHA risk cutpoints, the biomarker levels, or either drug algorithm [1]. It also carries the evidence weight of expert opinion, which is the right weight for a comparison of two documents but not the weight of a trial. Anyone who needs the actual numbers has to go to the guidelines themselves.
For how treatment escalates in this clinic, see /clinical/05-treatment-pathways.html.
This summary is provided for clinical decision support only and does not replace individualized clinical judgment. Findings are summarized from the cited primary sources; consult those sources before changing practice.
Version History
| Version | Date | Description |
|---|---|---|
| 1.0.0 | 2026-08-20 | Initial release |
References
- Finocchiaro S et al. Comparison of the 2025 ESC/EAS and 2026 ACC/AHA Guidelines for Dyslipidemia Management. European journal of preventive cardiology. 2026-08-11. doi:10.1093/eurjpc/zwag413. Available at: https://doi.org/10.1093/eurjpc/zwag413